|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600125940 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-01 17:30:45 |
|
注册时间: Date of Registration: |
2026-06-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
小脑iTBS联合虚拟现实机器人对卒中患者平衡与步行功能影响的研究 |
|
Public title: |
Effects of Cerebellar iTBS Combined with a Virtual Reality-Integrated Robotic System on Balance and Gait Functions in Stroke Patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
小脑iTBS联合虚拟现实机器人对卒中患者平衡与步行功能影响的研究 |
|
Scientific title: |
Effects of Cerebellar iTBS Combined with a Virtual Reality-Integrated Robotic System on Balance and Gait Functions in Stroke Patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张轶凡 |
研究负责人: |
黄丽萍 |
|
Applicant: |
Yifan Zhang |
Study leader: |
Liping Huang |
|
申请注册联系人电话: Applicant telephone: |
+86 181 3716 0576 |
研究负责人电话:
Study leader's |
+86 133 9190 8450 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhangyifan1936@163.com |
研究负责人电子邮件: Study leader's E-mail: |
ping-online@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国北京市海淀区复兴路28号 |
研究负责人通讯地址: |
中国北京市海淀区复兴路28号 |
|
Applicant address: |
No. 28 Fuxing Road, Haidian District, Beijing, China |
Study leader's address: |
No. 28 Fuxing Road, Haidian District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国人民解放军总医院 |
||
|
Applicant's institution: |
Chinese PLA General Hospital |
||
|
研究负责人所在单位: |
中国人民解放军总医院 |
||
|
Affiliation of the Leader: |
Chinese PLA General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理第S2026-277-01号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Chinese PLA General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-23 00:00:00 | ||
|
伦理委员会联系人: |
曹江 |
||
|
Contact Name of the ethic committee: |
Jiang Cao |
||
|
伦理委员会联系地址: |
中国北京市海淀区复兴路28号 |
||
|
Contact Address of the ethic committee: |
No. 28 Fuxing Road, Haidian District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 66937166 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国人民解放军总医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Chinese PLA General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国北京市海淀区复兴路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 28 Fuxing Road, Haidian District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
军队科研课题 |
||||||||||||||||||||||
|
Source(s) of funding: |
Military Scientific Research Project |
||||||||||||||||||||||
|
研究疾病: |
脑卒中 |
||||||||||||||||||||||
|
Target disease: |
Stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在探讨小脑iTBS与虚拟现实机器人联合应用于脑卒中平衡和步行功能康复的效果,同时采用肌电电和近红外光谱等技术评估,进一步探讨神经和肌肉重塑机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to investigate the therapeutic effect of combined application of cerebellar intermittent theta burst stimulation (iTBS) and virtual reality robotic rehabilitation on balance and walking function in stroke patients. Meanwhile, electromyography (EMG) and functional near-infrared spectroscopy (fNIRS) are adopted for evaluation, so as to further explore the mechanisms of neural and muscular remodeling. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.根据21世纪更新定义符合脑卒中诊断标准,通过CT或MRI等影像学检查明确诊断为单侧卒中; 2.年龄范围18-80岁; 3.首次、单侧发病; 4.发病时间1-6个月; 5.生命体征平稳,无或轻度认知障碍(MMSE≥21分),可以配合完成评估及治疗; 6.下肢Brunnstrom分期≥III期; 7.下肢Ashworth≤2级; 8.无颅骨缺损、脑水肿或脑萎缩。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Meet the diagnostic criteria for stroke updated in the 21st century, with a confirmed diagnosis of unilateral stroke verified by imaging examinations such as CT or MRI; 2.Aged between 18 to 80 years old; 3.First-ever and unilateral stroke onset; 4.Disease duration of 1 to 6 months after onset; 5.Stable vital signs; with no or mild cognitive impairment (MMSE score >= 21); able to cooperate with assessments and treatment procedures; 6.Lower limb Brunnstrom stage >= Stage III; 7. Lower limb Ashworth scale grade <= Grade 2; 8.No skull defect, cerebral edema or cerebral atrophy. |
||||||||||||||||||||||
|
排除标准: |
1.病情不稳定或存在认知障碍,无法配合治疗; 2.严重的心肺功能疾病,如心力衰竭、心肌梗死、哮喘发作、慢阻肺急性期等; 3.其他导致肢体运动功能障碍的病因(如关节炎、下肢溃破或其他肌骨系统疾病); 4.颅内金属植入物、电子植入设备、癫痫等经颅磁禁忌症; 5.头皮破损、伤口等,无法进行fnirs检测; 6.正在参与其他临床研究项目。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Unstable medical condition or cognitive impairment that results in inability to cooperate with treatment; 2. Severe cardiopulmonary diseases, such as heart failure, myocardial infarction, asthma attack, acute exacerbation of chronic obstructive pulmonary disease, etc; 3. Other etiologies causing limb motor dysfunction (e.g., arthritis, lower limb ulceration, or other musculoskeletal diseases); 4.Contraindications to transcranial magnetic stimulation, such as intracranial metal implants, electronic implanted devices, and epilepsy; 5. Scalp damage, wounds or other conditions that preclude fNIRS examination; 6.Participation in other ongoing clinical research projects. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-04-20 00:00:00至 To 2027-04-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-06-01 00:00:00 至 To 2027-04-20 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
基线评估后,所有符合条件的参与者将按照简单的随机化程序(www.randomizer.org)进行随机化。按照1:1:1:1的比例随机化分为干预组和三个对照组。保证结果评估人员对参与者的分组情况,以及两组人员预计发生的结果一无所知。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
After baseline assessment, all eligible participants will be randomized using a simple randomization procedure (www.randomizer.org). Participants will be allocated into the intervention group and three control groups at a 1:1:1:1 ratio. Outcome assessors will be kept blinded to participant group allocation and the expected outcomes of each group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲:评估者给予施盲。 |
|
Blinding: |
Single-blind: blinding evaluators. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2027年9月,经研究者同意后可邮箱申请获取方式; |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
In September, 2027, with the consent of the researcher, the acquisition method can be applied by email; |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集填写病例记录表,表单管理:验证结束后所有临床研究资料交临床试验机构保存至上市后5年。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection Fill in the case record form and form management: All clinical study data shall be submitted to the clinical trial institution after verification and kept for 5 years after listing. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |